An educational live and enduring activity provided by i3 Health has demonstrated knowledge gains and learning outcomes for nurses treating patients with castration-resistant prostate cancer (CRPC). Prostate cancer is the most common tumor type in men, affecting one in eight men in the United States. The estimate for 2022 is expecting 268,490 new cases of prostate cancer, with 34,500 of those cases resulting in death. The typical treatment for progressive prostate disease is androgen deprivation ...

The FDA has approved lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) (Pluvicto™, Advanced Accelerator Applications, Novartis) for the treatment of patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC) who have undergone treatment with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. In addition, the FDA approved gallium-68 gozetotide (68Ga-PSMA-11) (Locametz®, Novartis), a radioactive diagnostic agent ...

In this interview, Nicholas Vogelzang, MD, speaks with i3 Health about the recent FDA approval of rucaparib (Rubraca®, Clovis Oncology, Inc.) for the treatment of patients with metastatic BRCA-mutated castration-resistant prostate cancer (CRPC) who previously received one line of taxane-based chemotherapy and at least one line of androgen receptor-directed therapy. Dr. Vogelzang, Clinical Professor of Medicine at the University of Nevada School of Medicine and one of the investigators of the TRI...

The FDA has approved olaparib (LynparzaTM, AstraZeneca Pharmaceuticals LP) for adult patients with homologous recombination repair (HRR)–mutated metastatic castration-resistant prostate cancer (CRPC) who experience disease progression after treatment with enzalutamide or abiraterone acetate. In addition, the FDA approved two companion diagnostic devices: FoundationOne® CDx (Foundation Medicine, Inc.), for the identification of HRR gene alterations, and BRACAnalysis CDx®(Myriad Genetics, Inc...

In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still remain. In this interview with i3 Health, Judd W. Moul, MD, FACS, Professor of Urologic Surgery at the Duke School of Medicine, discusses strategies that community oncologists and urologists can utilize to determine the best treatment for their patients. He also discusses the rol...

​Androgen deprivation therapy is a cornerstone of treatment for progressive prostate cancer, but over time, many patients stop responding to this treatment, developing a resistance to castration. Until recently, nonmetastatic castration-resistant prostate cancer (CRPC) lacked effective treatment options; this situation has changed dramatically with the rise of several new agents. Metastatic CRPC is the primary cause of prostate-related mortality, yet advances in treatment are extending survival....

Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response. Baseline data collected from i3 Health's continuing me...

Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic castration-resistant prostate cancer (CRPC) is the primar...

Prostate cancer is the most common tumor type in men in the United States. Typically, androgen deprivation therapy (ADT) is administered for progressive disease. However, castration resistance or unresponsiveness to ADT or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic castration-resistant prostate cancer (CRPC) is the primary cause of prostate-re...

​Prostate cancer is the most common tumor type in men in the United States. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process that lacks effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, with a median overall survival that remains less than two years. In this interview with i3 Health, Alicia K. Morgans, MD, MPH, Associate Professor of Medicine at Northwestern University Feinberg School of Medicine, d...

​Prostate cancer is the most common tumor type in men in the United States. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process that lacks effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, with a median overall survival that remains less than two years. In this interview with i3 Health, Alicia K. Morgans, MD, MPH, Associate Professor of Medicine at Northwestern University Feinberg School of Medicine, d...

The FDA has now approved darolutamide (Nubeqa®, Bayer), an androgen receptor antagonist, for the treatment of nonmetastatic castration-resistant prostate cancer (CRPC). The approval was based on the ARAMIS phase 3 trial (NCT02200614), which enrolled 1,509 patients with nonmetastatic CRPC and a prostate-specific antigen doubling time of 10 months or less. Patients were randomized in a 2:1 ratio to receive darolutamide or placebo along with continued androgen deprivation therapy for a primary end ...